1392results about How to "Inhibit inflammation" patented technology

Methods and devices are disclosed for the non-invasive treatment of neurodegenerative diseases through delivery of energy to target nervous tissue, particularly the vagus nerve. The devices include a magnetic stimulator having coils with toroidal windings, which are in contact with an electrically conducting medium that is adapted to conform to the contour of a target body surface of a patient. The coils induce an electric current and / or an electric field within the patient, thereby stimulating nerve fibers within the patient. The stimulation brings about reduction of neuroinflammation in patients suffering from conditions comprising Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, postoperative cognitive dysfunction and postoperative delirium. Reduction in inflammation is effected by enhancing the anti-inflammatory competence of cytokines such as TGF-beta, wherein a retinoid or components of the retinoic acid signaling system provide an anti-inflammatory bias, by enhancing anti-inflammatory activity of a neurotrophic factor such as NGF, GDNF, BDNF, or MANF, and / or by inhibiting the activity of pro-inflammatory cytokines such as TNF-alpha.

An intracranial, light-emitting implant for providing therapy to a patient having Alzheimer's Disease.

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and / or therapeutic compositions, methods and devices.

An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. Another embodiment is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.

The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of skin volume as a result of aging, diseases, weight loss, and injury can lead to uneven skin surface (e.g. wrinkle, etc.). The uneven skin can be repaired by injecting appropriate amount of hollow fillers underneath the skin. Some cases of urinary incontinence occur when the resistance to urine flow has decreased excessively. Continence is restored by injecting the present invention to the urethra tissue to increase resistance to urine outflow. Similarly, the present invention allows for the control of gastric fluid reflux by submucosal injections of the fillers to the esophageal-gastric and gastric-pyloric junction. For patients with vesicoureteral reflux, it can be treated by injection of the present invention into patients' ureteral tissue. This invention can also be used to repair defective or inadequately functioning muscles of the anal sphincter by administering an effective amount of injectable hollow fillers into the defect or anal sinuses.

The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1, IL6 and other pro-inflammatory cytokines.

A topical cosmetic composition including: at least one water-soluble cosmetic agent; at least one oil-soluble cosmetic agent; and a dermal penetration enhancer, wherein topical application of the composition results in the delivery of the water-soluble and oil-soluble cosmetic agents into the stratum corneum as well as delivery of the oil-soluble cosmetic agent into the epidermis and dermis.

An anti-fungal composition, including: (a) an extract of botanical materials, the botanical materials including material from Echinacea species, and Propolis, which is a material derived from the hives of bees; and (b) an essential oil. The compositions of the present invention have been shown to have unexpectedly prolonged anti-fungal activity, as well as having anti-bacterial and anti-inflammatory activities. Preferably, the essential oil includes at least one oil selected from the group consisting of tea-tree oil, thyme oil and lavander oil. Also preferably, the herbal extract includes a mixture of Calendula, poke root, Echinacea and Propolis extract.

Disclosed is a stent assembly for expanding in vivo vessels, the assembly comprising first and second radially expandable mesh stents, wherein the first stent is separated by a predetermined distance from the second stent and a stent jacket spans the predetermined distance such that a first end of the jacket is operatively associated with the first stent and a second end of the jacket is operatively associated with the second stent.

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, A, W1, W2, and R′1 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Superantibodies having enhanced autophilic, catalytic, and / or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and / or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and / or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed.

Antibodies to IL-1-R intracellular ligand proteins are disclosed. The antibodies arc useful for inhibiting the binding between IL-1-R and IL-1-R intracellular ligand proteins.

The present invention relates to compositions and methods for modulating hair growth or regrowth. The compositions of the present invention comprise extracts of one or more of the following: Boswellia serrata, Undaria pinnatifida, green tea (e.g., Camellia sinensis), shiso, Pureraria mirifica, luteolin (e.g. Perilla ocymoides leaf extract), astilbin, vitamin E, amentoflavone, tetrahydropiperine, licochalcone, astaxanthin, red clover, Brassica juncea, unfermented green rooibos, enzyme CoQ10, salvia, ximenynic acid, hops oleoresin, apple, soy, saw palmetto, or ellagic extract, or any derivative thereof. In particular, the compositions and methods of the present invention can be used to stimulate or increase hair growth and / or prevent or slow the loss of hair by having one or more of the following functions: (a) inhibiting synthesis of DHT; (b) inhibiting proteasomal activity; (c) inhibiting IL-1 activity; (d) increasing vascularization; (e) increasing expression of vascular endothelial growth factor; (f) increasing expression of keratinocyte growth factor; (g) inhibiting inflammation; or (h) acting as an antibacterial.

Aspects of the present invention relate to NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor polynucleotides and polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in high endothelial venules endothelial cells (HEVECs) and endothelial cells from HEV-like vessels and small blood vessels, in connection with rheumatoid arthritis and Crohn's disease. Aspects of the invention also relates to drug screening assays for identifying compounds capable of modulating NF-HEV activity, wherein such compounds can be used in inhibiting or preventing chronic inflammation.

Methods and apparatuses (e.g., devices and systems) for vagus nerve stimulation, including (but not limited to) sub-diaphragmatic vagus nerve stimulation. In particular, the methods and apparatuses described herein may be used to stimulate the posterior sub-diaphragmatic vagus nerve to treat inflammation and / or inflammatory disorders. The implantable microstimulators described herein may be inductively charged and / or communicated with using the external charger. The implant may include a receiving antenna wrapped around the battery and / or the housing of the microstimulator / microregulator and / or may include a high magnetic permeability material in order to serve as a magnetic core for the antenna coil. Wearable inductive chargers / communication devices for inductively communicating with (including charging) an implanted microstimulator are described herein, which may include magnetically conductive material to enhance communication with an implant, including sub-diaphragmatic implants. Also described herein are inductive chargers / communication devices, including belts, and pads (e.g., mattresses) able to recharge an implanted neurostimulation device.

The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and / or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of α,α-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal absorption-promoting effect.

Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases.

The invention discloses a medlar and red date enzyme and a preparation method thereof, which belong to the technical field of enzyme preparation. Multi-strain composite fungi powder is adopted as a leavening agent; the medlar and the red date are adopted as main raw materials; dietary fiber, pectin hydrolyzate, seasoner extracting liquor, Chinese herbal medicine extracting liquor, enzyme stabilizer and other multifunctional auxiliary raw materials are scientifically compounded and modified; low-temperature processing technology such as ultrasonic cleaning, cryogenic grinding, microwave-assisted high-voltage pulse electric field processing and ultrasonic ripening are mainly adopted in the whole process, so that the natural colors, the flavor, the taste and the content of the active materials of the medlar and the red date are maintained furthest, the biological stability, the non-biological stability and the biological activity of the medlar and red date enzyme are obviously enhanced, the introduction of chemical addition agent is reduced, and the juicing rate of the medlar and the red date as well as the food safety of the enzyme are improved. Finally, the medlar and red date enzyme with high biological activity, strong stability, strong taste, flavor and appetite, long expiration date and edible safety is prepared.

The invention provides a drug-loading type guided tissue regeneration membrane and preparation method thereof. Polycaprolactone and other biodegradable aliphatic polyesters are used as raw materials and added with an antibacterial drug, and the materials are prepared into a single-layer guided tissue regeneration membrane through an electrospinning method. Or, polycaprolactone and degradable aliphatic polyester material are used as a dense layer, degradable natural polymer material and bio active particles are used as a loose layer, and an antibacterial drug is added to the dense layer; and the layers are prepared into a double-layer guided tissue regeneration membrane with different pore structures and biological activity through a layer by layer electrostatic spinning method. The membrane material provided by the invention has excellent biocompatibility, mechanical properties and degradation property consistent with tissue repair process, can effectively prevent the growth of fibroblasts towards tissue defects, at the same time promote the regeneration repair of tissue, does not have to taken out through a secondary operation; and the membrane material can effectively inhibit bacteria infection and inflammation after the operation, can be widely used in medical fields, such as guided tissue regeneration, postoperative adhesion prevention and drug delivery membrane.

A medical device includes an elongated sleeve having a longitudinal axis, a proximal end and a distal end. A cutting member extends distally from the distal end of the elongated sleeve, and has sharp cutting edges. The cutting head is formed from a wear-resistant ceramic material, and a motor coupled to the proximal end of elongated sleeve rotate the cutting member. The cutter is engaged against bone and rotated to cut bone tissue without leaving any foreign particles in the site.

The invention provides a double-layered bone repairing membrane material and a preparation method thereof and in particular provides a bone repairing membrane material with antibacterial and inflammation-diminishing and bone promotion functions and belongs to the field of biological materials. The material takes biodegradable aliphatic polyester with biocompatibility and natural polymers as main raw materials and is prepared by adopting an electrostatic spinning method. The material has a double-layered membrane structure and comprises an outer layer added with an antibacterial drug and an inner layer added with a bone promotion substance. The material provided by the invention has excellent biocompatibility and a controllable and long-period medicine releasing performance; meanwhile, an outer-layer membrane of the double-layered membrane structure can be used for inhibiting bacterial infection and inflammation, which are easily caused after bone defects occur, and preventing bacteria from entering defected parts; an inner-layer membrane can be used for promoting the repairing of the bone defects. The material can be used for realizing controllable in-vivo degradation according to requirements and the material does not need to be taken out by a second surgery.